Pages that link to "Q28289222"
Jump to navigation
Jump to search
The following pages link to Restoring function in exhausted CD8 T cells during chronic viral infection (Q28289222):
Displaying 50 items.
- Emerging concepts in the immunopathogenesis of AIDS (Q22241984) (← links)
- Vaccination for hepatitis C virus: closing in on an evasive target (Q22305922) (← links)
- Mesenchymal stem cells suppress T cells by inducing apoptosis and through PD-1/B7-H1 interactions (Q24305096) (← links)
- The immunoreceptor TIGIT regulates antitumor and antiviral CD8( ) T cell effector function (Q24307921) (← links)
- Retracted: The protein LEM promotes CD8⁺ T cell immunity through effects on mitochondrial respiration (Q24336998) (← links)
- Programmed death-1-induced interleukin-10 production by monocytes impairs CD4 T cell activation during HIV infection (Q24564396) (← links)
- Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150) (Q24599046) (← links)
- Posttranscriptional control of T cell effector function by aerobic glycolysis (Q24606942) (← links)
- HTLV-1 tax specific CD8 T cells express low levels of Tim-3 in HTLV-1 infection: implications for progression to neurological complications (Q24607794) (← links)
- Transient CD86 expression on hepatitis C virus-specific CD8 T cells in acute infection is linked to sufficient IL-2 signaling (Q24630036) (← links)
- The PD-1 pathway in tolerance and autoimmunity (Q24633549) (← links)
- Role of PD-1 in HIV pathogenesis and as target for therapy (Q24634293) (← links)
- The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? (Q24652185) (← links)
- BTLA mediates inhibition of human tumor-specific CD8 T cells that can be partially reversed by vaccination (Q24652965) (← links)
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. (Q24655516) (← links)
- Adoptive T cell therapy for cancer in the clinic (Q24680405) (← links)
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 T lymphocytes are prognostic factors of human ovarian cancer (Q24685406) (← links)
- PD-L1 expression in human cancers and its association with clinical outcomes (Q26738361) (← links)
- Effector, Memory, and Dysfunctional CD8( ) T Cell Fates in the Antitumor Immune Response (Q26744527) (← links)
- Modulation of Innate Immune Mechanisms to Enhance Leishmania Vaccine-Induced Immunity: Role of Coinhibitory Molecules (Q26744635) (← links)
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy (Q26745516) (← links)
- The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints (Q26745842) (← links)
- Immunotherapy for cancer in the central nervous system: Current and future directions (Q26750765) (← links)
- Starved and Asphyxiated: How Can CD8( ) T Cells within a Tumor Microenvironment Prevent Tumor Progression (Q26767514) (← links)
- Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis (Q26769728) (← links)
- Expanding the antimalarial toolkit: Targeting host-parasite interactions (Q26772866) (← links)
- Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C (Q26773283) (← links)
- Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies (Q26775034) (← links)
- Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy (Q26779184) (← links)
- CD8( )CD122( ) T-Cells: A Newly Emerging Regulator with Central Memory Cell Phenotypes (Q26779422) (← links)
- Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy (Q26781481) (← links)
- New developments in the management of advanced melanoma - role of pembrolizumab (Q26781931) (← links)
- CD1d- and MR1-Restricted T Cells in Sepsis (Q26796132) (← links)
- Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity (Q26796292) (← links)
- Pembrolizumab (Q26796435) (← links)
- Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer (Q26798047) (← links)
- Molecular and cellular insights into T cell exhaustion (Q26800047) (← links)
- Association of HLA-alleles with the immune regulation of chronic viral infections (Q26823033) (← links)
- Universes collide: combining immunotherapy with targeted therapy for cancer (Q26825316) (← links)
- Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck (Q26828598) (← links)
- Transplantation tolerance and its outcome during infections and inflammation (Q26829817) (← links)
- Overcoming T cell exhaustion in infection and cancer (Q26829885) (← links)
- Interleukin-27: balancing protective and pathological immunity (Q26830400) (← links)
- The importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathy (Q26859307) (← links)
- T-cell exhaustion in allograft rejection and tolerance (Q26865338) (← links)
- From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors (Q26865532) (← links)
- Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions (Q26865859) (← links)
- Immunotherapy advances for glioblastoma (Q26866513) (← links)
- Genetic engineering with T cell receptors (Q26995677) (← links)
- Optimal management of metastatic melanoma: current strategies and future directions (Q26997338) (← links)